235. 副甲状腺機能低下症 Disease details / Clinical trials / Drug dev / DR info

100mcg rhPTH(1-84)
   Shire
      2017   Phase 1   NCT02781844   Canada;Denmark;Hungary;United States;
25mcg rhPTH(1-84)
   Shire
      2017   Phase 1   NCT02781844   Canada;Denmark;Hungary;United States;
50mcg rhPTH(1-84)
   Shire
      2017   Phase 1   NCT02781844   Canada;Denmark;Hungary;United States;
A: PTH (1-84)
   University of Aarhus
      2008   Phase 2   NCT00730210   Denmark;
AZP-3601
   Amolyt Pharma
      2020   Phase 1   NCT05239221   Hungary;Netherlands;
Alfacalcidol
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2016   Phase 2   EUCTR2016-000500-29-FR   France;
   Assistance Publique - Hôpitaux de Paris
      2017   Phase 2   NCT02824718   France;
Allogenic parathyroid cells
   Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
      2022   Phase 1/Phase 2   NCT05186883   -
Amorphous calcium carbonate
   Amorphical Ltd.
      2013   Phase 1/Phase 2   NCT01815021   Israel;
Autofluorescent detection + Injection of indocyanine green
   Onze Lieve Vrouw Hospital
      2021   Phase 3   NCT05117853   Belgium;
Blood sample
   Hospices Civils de Lyon
      2021   -   NCT04671719   France;
CLTX-305
   National Institute of Dental and Craniofacial Research (NIDCR)
      2020   Phase 2   NCT04465227   United States;
Calcitriol
   CHU de Quebec-Universite Laval
      2017   -   NCT03249012   Canada;
   Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine
      2021   Phase 1-2   ChiCTR2100041719   China;
Calcitriol & Calcium
   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
      1991   Phase 2   NCT00001304   United States;
Calcium
   Hospices Civils de Lyon
      2019   -   NCT04126941   France;
   Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine
      2021   Phase 1-2   ChiCTR2100041719   China;
   West China Hospital, Sichuan University
      2019   -   ChiCTR1900022194   China;
Calcium carbonate
   CHU de Quebec-Universite Laval
      2017   -   NCT03249012   Canada;
   Hokusetsu ROD Study Group
      2006   -   JPRN-UMIN000000475   Japan;
Calcium carbonate and alphacalcidol
   University of Athens
      2017   -   NCT04146259   Greece;
Calcium gluconate
   National Center for Research Resources (NCRR)
      1995   -   NCT00004361   -
Calcium lactate
   kawasaki medicak school
      2009   Phase 3   JPRN-UMIN000002155   Japan;
Combination Product: TransCon PTH
   Ascendis Pharma A/S
      2019   Phase 2   NCT04009291   Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States;
   Ascendis Pharma Bone Diseases A/S
      2021   Phase 3   NCT04701203   Canada;Denmark;Germany;Hungary;Italy;Norway;United States;
Control group
   University Hospital, Brest
      2021   Phase 3   NCT04785443   France;
Crystalline calcium supplements
   Amorphical Ltd.
      2013   Phase 1/Phase 2   NCT01815021   Israel;
Dexamethasone oral tablet 8mg (Dexamethasone Krka tablets(8mg), Warsaw, Poland).
   Medical University of Lodz
      2020   Phase 4   NCT04412694   Poland;
EB612 (EBP05)
   Entera Bio Ltd.
      2018   Phase 2   NCT03516773   Israel;
ESIDREX-R
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2016   Phase 2   EUCTR2016-000500-29-FR   France;
EnteraBio's Oral Parathyroid Hormone (1-34)
   Entera Bio Ltd.
      2014   Phase 2   NCT02152228   Israel;
FORSTEO-R
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2016   Phase 2   EUCTR2016-000500-29-FR   France;
Gold standard of visual identification and evaluation of viability of the parathyroid glands.
   Onze Lieve Vrouw Hospital
      2021   Phase 3   NCT05117853   Belgium;
Human recombinant parathyroid Hormone
   Shire Human Genetic Therapies, Inc.
      2018   Phase 3   EUCTR2017-003067-36-HU   Canada;Denmark;Hungary;United States;
      2018   Phase 3   EUCTR2017-003067-36-DK   Canada;Denmark;Hungary;United States;
Human recombinant parathyroid hormone
   Shire Human Genetic Therapies, Inc.
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-SE   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-PT   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-NL   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-GB   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-DK   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-BE   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States;
Hydrochlorothiazide
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2016   Phase 2   EUCTR2016-000500-29-FR   France;
ICG
   University Hospital, Brest
      2021   Phase 3   NCT04785443   France;
INN Parathyroid Hormone (1-84) human
   NPS Pharmaceuticals, Inc.
      2015   Phase 1   EUCTR2015-003108-22-GB   United Kingdom;
Immediate post operative bioassay of Parathyroid Hormone
   Centre Hospitalier Universitaire de Nimes
      2012   -   NCT02924532   -
Infracyanine
   CHRU de Brest
      2021   Phase 3   EUCTR2020-005189-32-FR   France;
Magnesium
   University of Tartu
      2009   -   NCT00824226   Estonia;
NATPARA/NATPAR
   Entera Bio Ltd.
      2018   Phase 2   NCT03516773   Israel;
NPSP 558
   NPS PHARMACEUTICALS
      2009   -   EUCTR2008-005063-34-IT   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom;
   NPS Pharmaceuticals, Inc.
      2015   Phase 1   EUCTR2015-003108-22-GB   United Kingdom;
      2011   -   EUCTR2011-001265-40-HU   Hungary;
      2010   -   EUCTR2008-005063-34-LT   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom;
      2010   -   EUCTR2008-005063-34-HU   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom;
      2009   Phase 3   EUCTR2008-005063-34-GB   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom;
      2009   -   EUCTR2008-005063-34-FR   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom;
      2009   -   EUCTR2008-005063-34-DK   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom;
      2008   Phase 3   EUCTR2008-005063-34-BE   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom;
NPSP558
   Shire
      2011   Phase 3   NCT01455181   Hungary;
      2011   Phase 3   NCT01297309   United States;
      2011   Phase 3   NCT01268098   United States;
      2008   Phase 3   NCT00732615   Belgium;Canada;Denmark;France;Hungary;Italy;United Kingdom;United States;
Natpar
   Shire Human Genetic Therapies, Inc.
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-SE   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-PT   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-NL   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-GB   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-DK   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-BE   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States;
Natpara
   Shire Human Genetic Therapies, Inc.
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-IT   Belgium;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-003067-36-HU   Canada;Denmark;Hungary;United States;
      2018   Phase 3   EUCTR2017-003067-36-DK   Canada;Denmark;Hungary;United States;
Near-infrared-induced autofluorescence and indocyanine green near-infrared angiography
   Odense University Hospital
      2021   -   NCT05130476   Denmark;
ORMONE PARATIROIDEO DA DNA RICOMBINANTE
   Shire Human Genetic Therapies, Inc.
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-IT   Belgium;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States;
Open-label PTH(1-84)
   John P. Bilezikian
      2009   Phase 3   NCT01199614   United States;
PCO371
   Chugai Pharmaceutical
      2020   Phase 1   NCT04209179   Canada;Hungary;United States;
POLY(OXY-1,2-ETHANEDIYL), A
   Ascendis Pharma Bone Diseases A/S
      2019   Phase 2   EUCTR2018-004815-33-DK   Canada;Denmark;Germany;United Kingdom;United States;
POLY(OXY-1,2-ETHANEDIYL), ALPHA-HYDRO-OMEGA-METHOXY, ETHER WITH N-[[[2-
   Ascendis Pharma Bone Disease A/S
      2021   Phase 3   EUCTR2020-003380-26-IT   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States;
POLY(OXY-1,2-ETHANEDIYL), ALPHA-HYDRO-OMEGA-METHOXY, ETHER WITH N-[[[2-[[6-[[1-[3-[[3-(2,3-DIHYDROXYPROPOXY)PROPYL]AMINO]-3-OXOPROPYL]-2,5-DI
   Ascendis Pharma Bone Diseases A/S
      2021   Phase 3   EUCTR2020-003380-26-DK   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003380-26-DE   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-003380-26-NO   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States;
POLY(OXY-1,2-ETHANEDIYL), ALPHA-HYDRO-OMEGA-METHOXY, ETHER WITH N-[[[2-[[6-[[1-[3-[[3-(2,3-DIHYDROXYPROPOXY)PROPYL]AMINO]-3-OXOPROPYL]-2,5-DIOXO-3-PYRROLIDINYL]THIO]HEXYL]AMINO]ETHYL]AMINO]CARBONYL]-2-METHYLALANYL-TERIPARATIDE (2:1)
   Ascendis Pharma Bone Diseases A/S
      2021   Phase 3   EUCTR2020-003380-26-HU   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003380-26-FR   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003380-26-DK   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003380-26-DE   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-003380-26-NO   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004815-33-NO   Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004815-33-GB   Canada;Denmark;Germany;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004815-33-DK   Canada;Denmark;Germany;United Kingdom;United States;
      -   Phase 2   EUCTR2018-004815-33-DE   Canada;Denmark;Germany;United States;
PTH
   CHU de Quebec-Universite Laval
      2017   -   NCT03249012   Canada;
   Chessler D. Steven
      2021   Phase 3   JPRN-jRCT2051210058   Japan;
   Hospital de Niños R. Gutierrez de Buenos Aires
      2014   -   NCT04690842   -
   John P. Bilezikian
      2004   Phase 2/Phase 3   NCT00473265   United States;
   Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine
      2021   Phase 1-2   ChiCTR2100041719   China;
   kawasaki medicak school
      2009   Phase 3   JPRN-UMIN000002155   Japan;
PTH 1-34
   National Institute of Dental and Craniofacial Research (NIDCR)
      2006   Phase 3   NCT00395538   Austria;Italy;United States;
PTH1-84 in parent study
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2010   Phase 3   NCT00856401   United States;
Palopegteriparatide
   Ascendis Pharma Bone Diseases A/S
      2021   Phase 3   EUCTR2020-003380-26-DK   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003380-26-DE   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-003380-26-NO   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States;
Parathyroid Hormone (1-84) Human Recombinant
   NPS Pharmaceuticals, Inc.
      2015   Phase 1   EUCTR2015-003108-22-GB   United Kingdom;
Parathyroid Hormone (rDNA)
   NPS Pharmaceuticals, Inc.
      2015   Phase 1   EUCTR2015-003108-22-GB   United Kingdom;
Parathyroid hormon 1-84
   University of Bergen
      2016   Early Phase 1   NCT02986607   Norway;
Parathyroid hormone
   Takeda Pharmaceutical Company Limited
      2021   Phase 3   JPRN-JapicCTI-194828   Japan;
Parathyroid hormone (rdna)
   Aarhus University Hospital, Dept of Endocrinology and Metabolism C
      2008   Phase 4   EUCTR2008-000606-36-DK   Denmark;
Parathyroideahormon
   Aarhus University Hospital, Dept of Endocrinology and Metabolism C
      2008   Phase 4   EUCTR2008-000606-36-DK   Denmark;
Phosphate
   Hokusetsu ROD Study Group
      2006   -   JPRN-UMIN000000475   Japan;
Phosphate and betamethasone acetate, 2 mL.
   Hospital Italiano de Buenos Aires
      2016   Phase 4   NCT02652884   Argentina;
Potassium sparing diuretic
   Assistance Publique - Hôpitaux de Paris
      2017   Phase 2   NCT02824718   France;
Preotact
   Aarhus University Hospital, Dept of Endocrinology and Metabolism C
      2008   Phase 4   EUCTR2008-000606-36-DK   Denmark;
RECOMBINANT HUMAN PARATHYROID HORMONE (1-84)
   Shire Human Genetic Therapies, Inc.
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-SE   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-PT   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-NL   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-GB   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-DK   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-BE   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States;
Rcombinant Human Parathyroid Hormone [rhPTH(1-84)]
   NPS Pharmaceuticals, Inc.
      2010   -   EUCTR2008-005063-34-LT   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom;
      2010   -   EUCTR2008-005063-34-HU   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom;
      2009   Phase 3   EUCTR2008-005063-34-GB   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom;
      2009   -   EUCTR2008-005063-34-FR   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom;
      2009   -   EUCTR2008-005063-34-DK   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom;
      2008   Phase 3   EUCTR2008-005063-34-BE   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom;
Recombinant Human Parathyroid Hormone [rhPTH(1-84)]
   NPS Pharmaceuticals, Inc.
      2011   -   EUCTR2011-001265-40-HU   Hungary;
      2010   -   EUCTR2008-005063-34-LT   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom;
      2010   -   EUCTR2008-005063-34-HU   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom;
      2009   Phase 3   EUCTR2008-005063-34-GB   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom;
      2009   -   EUCTR2008-005063-34-FR   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom;
      2009   -   EUCTR2008-005063-34-DK   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom;
      2008   Phase 3   EUCTR2008-005063-34-BE   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom;
RhPTH (1-84)
   Takeda Pharmaceutical Company Limited
      2021   Phase 3   JPRN-JapicCTI-194828   Japan;
RhPTH(1-84)
   Shire
      2022   Phase 3   NCT03878953   Japan;
      2018   Phase 4   NCT03324880   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   NCT03364738   Canada;Denmark;Hungary;United States;
      2017   Phase 1   NCT03150108   United States;
      2016   Phase 4   NCT02910466   United States;
   Shire Human Genetic Therapies, Inc.
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-SE   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-PT   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-NL   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-GB   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-DK   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-BE   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-003067-36-HU   Canada;Denmark;Hungary;United States;
      2018   Phase 3   EUCTR2017-003067-36-DK   Canada;Denmark;Hungary;United States;
SUB21634
   Aarhus University Hospital, Dept of Endocrinology and Metabolism C
      2008   Phase 4   EUCTR2008-000606-36-DK   Denmark;
Saline NaCl
   Hospital Italiano de Buenos Aires
      2016   Phase 4   NCT02652884   Argentina;
Sevelamer
   Hokusetsu ROD Study Group
      2006   -   JPRN-UMIN000000475   Japan;
Sodium citrate
   National Center for Research Resources (NCRR)
      1995   -   NCT00004361   -
Synthetic Human Parathyroid Hormone 1-34
   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
      2008   Early Phase 1   NCT00743782   United States;
      1991   Phase 2   NCT00001304   United States;
Te
   Ascendis Pharma Bone Disease A/S
      2021   Phase 3   EUCTR2020-003380-26-IT   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States;
Teriparatide
   Assistance Publique - Hôpitaux de Paris
      2017   Phase 2   NCT02824718   France;
   Mayo Clinic
      2010   Phase 2   NCT01171690   United States;
   Saint Petersburg State University, Russia
      2021   Phase 3   NCT04750460   Russian Federation;
   The Seventh Medical Center, PLA General Hospital
      2021   -   ChiCTR2100047758   China;
Teriparatide conjugated to a multiarm polyethylene glycol carrier molecule through a cleava
   Ascendis Pharma Bone Diseases A/S
      2021   Phase 3   EUCTR2020-003380-26-HU   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003380-26-FR   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States;
Teriparatide conjugated to a multiarm polyethylene glycol carrier molecule through a cleavable linker
   Ascendis Pharma Bone Disease A/S
      2021   Phase 3   EUCTR2020-003380-26-IT   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004815-33-IT   Canada;Denmark;Germany;Italy;United Kingdom;United States;
   Ascendis Pharma Bone Diseases A/S
      2021   Phase 3   EUCTR2020-003380-26-HU   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003380-26-FR   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004815-33-NO   Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004815-33-GB   Canada;Denmark;Germany;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004815-33-DK   Canada;Denmark;Germany;United Kingdom;United States;
      -   Phase 2   EUCTR2018-004815-33-DE   Canada;Denmark;Germany;United States;
Thiazide
   Assistance Publique - Hôpitaux de Paris
      2017   Phase 2   NCT02824718   France;
Thymus/Parathyroid Transplantation
   M. Louise Markert
      2005   Phase 1   NCT00566488   United States;
Total thyroidectomy
   Medical University of Lodz
      2020   Phase 4   NCT04412694   Poland;
TransCon PTH high-dose pen
   Ascendis Pharma Bone Disease A/S
      2021   Phase 3   EUCTR2020-003380-26-IT   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004815-33-IT   Canada;Denmark;Germany;Italy;United Kingdom;United States;
   Ascendis Pharma Bone Diseases A/S
      2021   Phase 3   EUCTR2020-003380-26-HU   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003380-26-FR   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003380-26-DK   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003380-26-DE   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-003380-26-NO   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004815-33-NO   Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004815-33-GB   Canada;Denmark;Germany;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004815-33-DK   Canada;Denmark;Germany;United Kingdom;United States;
      -   Phase 2   EUCTR2018-004815-33-DE   Canada;Denmark;Germany;United States;
TransCon PTH low-dose pen
   Ascendis Pharma Bone Disease A/S
      2021   Phase 3   EUCTR2020-003380-26-IT   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004815-33-IT   Canada;Denmark;Germany;Italy;United Kingdom;United States;
   Ascendis Pharma Bone Diseases A/S
      2021   Phase 3   EUCTR2020-003380-26-HU   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003380-26-FR   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003380-26-DK   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003380-26-DE   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-003380-26-NO   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004815-33-NO   Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004815-33-GB   Canada;Denmark;Germany;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004815-33-DK   Canada;Denmark;Germany;United Kingdom;United States;
      -   Phase 2   EUCTR2018-004815-33-DE   Canada;Denmark;Germany;United States;
TransCon PTH mid-dose pen
   Ascendis Pharma Bone Disease A/S
      2021   Phase 3   EUCTR2020-003380-26-IT   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004815-33-IT   Canada;Denmark;Germany;Italy;United Kingdom;United States;
   Ascendis Pharma Bone Diseases A/S
      2021   Phase 3   EUCTR2020-003380-26-HU   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003380-26-FR   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003380-26-DK   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States;
      2021   Phase 3   EUCTR2020-003380-26-DE   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-003380-26-NO   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004815-33-NO   Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004815-33-GB   Canada;Denmark;Germany;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-004815-33-DK   Canada;Denmark;Germany;United Kingdom;United States;
      -   Phase 2   EUCTR2018-004815-33-DE   Canada;Denmark;Germany;United States;
Tériparatide
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2016   Phase 2   EUCTR2016-000500-29-FR   France;
UN-ALPHA-R 0.25µg
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2016   Phase 2   EUCTR2016-000500-29-FR   France;
Verde de Indocianina (Indocyanine Green)
   Hospital Universitari Son Espases
      2020   Phase 4   EUCTR2019-003506-26-ES   Spain;
Vitamin D
   University of Wisconsin, Madison
      2005   Phase 4   NCT00581828   United States;
   West China Hospital, Sichuan University
      2019   -   ChiCTR1900022194   China;